BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In chronic myeloid leukemia (CML), peptides encompassing the BCR-ABL fusion site in theory represent optimal targets for immunotherapy, as this fusion protein is essential for the malignant transformation, is present in virtually all CML cells and patients, and potentially provides HLA binding motifs.